- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872261
Determining Characteristics and Behaviors of Adolescent Women Regarding HIV Risk and Microbicide Trial Participation
Adolescent Women & Microbicide Trials: Assessing the Challenges & Opportunities to Their Participation
Study Overview
Status
Conditions
Detailed Description
HIV is an infection that damages a person's immune system and can develop into AIDS. More than 10 million women between the ages of 15 and 24 currently live with HIV or AIDS, most of them in sub-Saharan Africa and Asia. The rate of infections in women is high in part because they may not be able to use existing HIV prevention methods: remaining abstinent does not help if their partner is not also abstinent and using a male condom requires the compliance of the male. Oral and topical microbicides are products women initiate using to reduce their risk of HIV infection. Several clinical trials of these products have been conducted, but few have tested populations of young women, who may have different characteristics or behaviors from other women. This study will collect data on the characteristics and behaviors of women divided into two age groups, women age 15 to 17 and women age 18 to 21, in both Tanzania and India. This study will have four goals: (1) to determine whether and how characteristics that put women at risk for HIV differ in these age and country groups; (2) to evaluate the legal, social, cultural, and delivery factors that hinder women's participation in microbicide trials; (3) to examine the understanding and ability of women in these different groups to adhere to the requirements of clinical trial participation; and (4) to determine young women's acceptability and use of a practice gel or pill.
This study will consist of three phases. The first phase will address the first two goals by conducting repeated, in-depth interviews and discussions with a small group of sexually active adolescents in India and Tanzania, followed up by interviews with informants and relevant community members. These interviews and discussions will address differences in HIV risk characteristics between groups of women and the legal, social, cultural, and delivery factors hindering women's participation in microbicide trials. The second phase will consist of a series of workshops to define and describe a set of youth-friendly procedures for using microbicides. Community members and researchers will participate in these workshops, and some adolescents will be invited to pretest the study instruments.
The third phase will be a pilot clinical study that addresses the second two goals by asking participants to undergo evaluations over time, similar to the way they would have to in a microbicide trial. Participants will complete study visits at baseline and after 2, 4, and 6 months, during which time they will answer questions about their sexual relationships and use of risk reduction behaviors. They will also provide urine, blood, and endo-cervical swab samples for testing for pregnancy, HIV, and sexually transmitted infection. Between the 4- and 6-month visits, participants will also be asked to participate in a 2-month substudy in which they use proxy pills or gels. They will then complete interviews about their experiences using the pills or gels. Some participants who decline to participate will be invited to complete brief interviews about why they chose not to participate.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Dar es Salaam, Tanzania
- Muhimbili University of Health and Allied Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Formative research will recruit adolescents and other participants from community samples in Pune, India and Dar es Salaam, Tanzania.
Pilot clinical study will recruit adolescents from India and Tanzania through healthcare facilities, nongovernmental organizations, and other mechanisms.
Description
Inclusion Criteria:
- Sexually active in the 3 months prior to screening
- Willing to provide biological samples and answer questions about sexual behaviors
Exclusion Criteria:
- Pregnancy
- HIV infected
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Proxy microbicide product
Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Presence of sexually transmitted infections, such as chlamydia, gonorrhea, genital herpes, or HIV
Time Frame: Measured at baseline and after 4 months
|
Measured at baseline and after 4 months
|
Adherence to condom use
Time Frame: Measured over 6 months
|
Measured over 6 months
|
Reasons for nonparticipation in clinical study
Time Frame: Measured at screening
|
Measured at screening
|
Retention, defined as the proportion of follow-up visits during the measurement window
Time Frame: Measured over 6 months
|
Measured over 6 months
|
Proportion of participants recruited into the microbicide substudy
Time Frame: Measured over 2 months
|
Measured over 2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Description of sexual risk patterns and psychosocial mediators of risk
Time Frame: Measured during formative research and during the 6-month pilot clinical study
|
Measured during formative research and during the 6-month pilot clinical study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth E. Tolley, PhD, FHI 360
- Principal Investigator: Sylvia Kaaya, PhD, Muhimbili University of Health and Allied Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MH086160 (U.S. NIH Grant/Contract)
- DAHBR 9A-ASPA (National Institute of Mental Health)
- Tolley 1 R01 MH086160-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed